Aspirin in Reducing Events in the Elderly eXTension (ASPREE-XT)

ASPREE (ASPirin in Reducing Events in the Elderly) was a joint US/Australian randomized clinical trial aiming to determine whether low-dose aspirin increases healthy life-span, defined as survival free of dementia and disability. ASPREE began in 2010 and completed recruitment in 2014. It was a randomized, double-blind, placebo controlled, primary prevention trial of daily 100 mg of aspirin in older people free of cardiovascular disease, dementia and physical disability in the United States (US) and Australia with a period of follow-up averaging 4.5 years. ASPREE's primary outcome was duration of survival free of dementia and persistent physical disability and had secondary outcomes encompassing the major health issues related to aging. The trial involving 19,114 persons aged 70 and above (65 years and above for US minorities) is distinctive for its large size, methodological rigor and high participant retention rate in both countries. ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants that began in January 2018. This enables the monitoring of possible legacy effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition, the large well-characterized cohort with extended follow-up and a range of health outcomes provides a unique opportunity to study health and resilience in older individuals.

老年人群阿司匹林事件减少研究（ASPREE，ASPirin in Reducing Events in the Elderly）是一项美澳联合开展的随机临床试验，旨在明确低剂量阿司匹林是否可延长健康寿命——即无痴呆与躯体残疾的生存时长。该研究于2010年启动，2014年完成受试者招募，针对美国与澳大利亚境内无心血管疾病、痴呆及躯体残疾的老年人，开展每日服用100mg阿司匹林的随机双盲安慰剂对照一级预防试验，平均随访时长为4.5年。
该研究的主要结局为无痴呆与持续性躯体残疾的生存时长，次要结局则涵盖与衰老相关的各类主要健康问题。
此项试验共纳入19114名70岁及以上受试者（美国少数族裔受试者的年龄门槛为65岁及以上），以样本规模庞大、方法学严谨及两国受试者高保留率而独具特色。
ASPREE-XT是针对ASPREE受试者开展的治疗后纵向观察性随访研究，于2018年1月启动，旨在监测阿司匹林治疗可能产生的遗留效应，核心聚焦于癌症发病率、肿瘤转移及死亡率。
此外，该经过充分表征的大型队列结合延长随访周期与多维度健康结局数据，为探究老年人的健康状况与韧性提供了独一无二的研究契机。